2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1488

Correlation between Lung Ultrasound, HRCT Findings and Pulmonary Function Tests in Primary Sjögren’s Syndrome (pSS)-Associated Interstitial Lung Disease
Abstract Number: 818

Correlation between the Routine Assessment of Patient Index Data (RAPID3) and Inflammatory Markers in Patients with PMR
Abstract Number: 1458

Correlation of Multi-Biomarker Disease Activity Score with Clinical Disease Activity Measures for the JAK1-Selective Inhibitor Filgotinib As Monotherapy and in Combination with Methotrexate in Rheumatoid Arthritis Patients
Abstract Number: 734

Correlation of the American College of Rheumatology Provisional Composite Response Index in Systemic Sclerosis with Serum Biomarkers of Fibrogenesis in an Observational Cohort
Abstract Number: 1365

Correlation of the Multi-Biomarker Disease Activity Score with Composite Rheumatoid Arthritis Disease Activity Measures: A Systematic Review and Meta-Analysis
Abstract Number: 2340

Correlation of Type I Interferon Score and CXCL10 (C-X-C Motif Chemokine Ligand 10) with Cutaneous and Muscular Disease Activity in Juvenile Dermatomyositis Patients
Abstract Number: 252

Correlations between Clinical and Ultrasound Scores of Peripheral Enthesitis and Disease Activity Scores in a Cohort of Spondyloarthritis
Abstract Number: 1442

Corticosteroid Sparing Effect of Non-TNF Targeted Biologics, Rituximab, Abatacept and Tocilizumab in Common Practice: Data from 3183 Patients Enrolled in the French Society of Rheumatology Registries
Abstract Number: 278

Corticosteroid Use, Biologic Therapy Switching, Smoking and Renal Failure Are Associated with Serious Infections in Rheumatoid Arthritis Patients Treated with Biologics: Data from Two Latin-American Registries
Abstract Number: 2888

Corticosteroid-Sparing Benefit of Intravenous Immunoglobulins in Systemic Sclerosis-Associated Inflammatory Myopathy: A Retrospective Study of 54 Patients
Abstract Number: 1465

Cost per Response for Abatacept Versus Adalimumab in Patients with Seropositive, Erosive, Early Rheumatoid Arthritis in the US, Germany, Spain and Canada
Abstract Number: 2833

Cost-Effectiveness of Competing Anticoagulation Strategies in Knee Replacement Patients
Abstract Number: 1047

Cost-Effectiveness of Drug-Level Guided Adalimumab Dosing
Abstract Number: 1059

Cost-Effectiveness of Tai Chi Versus Physical Therapy for Knee Osteoarthritis
Abstract Number: 1199

Costs Associated with Osteoarthritis Care Using Intra-Articular Hyaluronic Acid: Analysis of an Administrative Database

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].